20 July 2022
ANANDA
DEVELOPMENTS PLC
(“Ananda” or the “Company”)
NOTICE OF ANNUAL
GENERAL MEETING
Ananda announces that Notice convening the Company’s Annual
General Meeting (“AGM”) for 10.00 on Wednesday, 17 August 2022 at the offices of Shakespeare
Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V OHR, has been sent to
shareholders in the Company.
In addition to the usual resolutions at the AGM, resolutions
will also be proposed to approve an Enterprise Management Incentive
(‘EMI’) Plan and an Unapproved Share Option Plan. Details of these
plans are available within the Notice of Meeting, available at
https://anandadevelopments.com/publications/ under the Notices and
Meetings tab, and the rules of the schemes will be available at
https://anandadevelopments.com/publications/ under the Company
Documents tab. The EMI plan is intended to be used in order to
allow the operational team currently undertaking the Company’s
genetic stabilisation research programme and commercial
trials to participate in the Company as shareholders. The
Unapproved plan is being established in order to allow any Senior
management excluded from participating in the EMI to still be
afforded the same opportunity.
The AGM will also consider, pursuant to section 656 of the
Companies Act 2006, whether any, and if so what, steps should be
taken to address the fact that the net assets of the Company have
fallen to half or less of its called-up share capital. This is a
technical accounting outcome and the Directors do not believe that
this will otherwise impact the Company.
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS
PLC
Chief Executive Officer
Melissa Sturgess
Investor Relations
Jeremy Sturgess-Smith |
+44 (0) 7463 686
497
ir@anandadevelopments.com |
PETERHOUSE CAPITAL
LIMITED
Corporate Finance
Mark Anwyl
Corporate Broking
Lucy Williams
Duncan Vasey |
+44 (0)20 7469
0930 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company creating
UK-based operations to grow and provide carbon zero, consistent,
medical cannabis for the UK and international markets.
The UK medical cannabis market is predicted to be worth £450m by
2025 and the European market is predicted to be worth USD4.2bn by 2027.
For more information, please
visit: https://anandadevelopments.com/
